BRPI0907237A2 - Anticorpo anti-cldn6 - Google Patents

Anticorpo anti-cldn6

Info

Publication number
BRPI0907237A2
BRPI0907237A2 BRPI0907237-3A BRPI0907237A BRPI0907237A2 BR PI0907237 A2 BRPI0907237 A2 BR PI0907237A2 BR PI0907237 A BRPI0907237 A BR PI0907237A BR PI0907237 A2 BRPI0907237 A2 BR PI0907237A2
Authority
BR
Brazil
Prior art keywords
cldn6 antibody
cldn6
antibody
Prior art date
Application number
BRPI0907237-3A
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Shuichi Tsutsumi
Kunihiro Nishimura
Hirofumi Sakumoto
Shigeto Kawai
Original Assignee
Univ Tokyo
Forerunner Pharma Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907237(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tokyo, Forerunner Pharma Res Co Ltd filed Critical Univ Tokyo
Publication of BRPI0907237A2 publication Critical patent/BRPI0907237A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0907237-3A 2008-01-11 2009-01-09 Anticorpo anti-cldn6 BRPI0907237A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008004423 2008-01-11
PCT/JP2009/000082 WO2009087978A1 (ja) 2008-01-11 2009-01-09 抗cldn6抗体

Publications (1)

Publication Number Publication Date
BRPI0907237A2 true BRPI0907237A2 (pt) 2015-07-14

Family

ID=40853092

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907237-3A BRPI0907237A2 (pt) 2008-01-11 2009-01-09 Anticorpo anti-cldn6

Country Status (12)

Country Link
US (1) US9274119B2 (pt)
EP (3) EP2241578B1 (pt)
JP (1) JP5848863B2 (pt)
KR (1) KR20100116179A (pt)
CN (1) CN101918450A (pt)
AU (1) AU2009203464A1 (pt)
BR (1) BRPI0907237A2 (pt)
CA (1) CA2711557A1 (pt)
MX (1) MX2010007500A (pt)
RU (1) RU2010133547A (pt)
SG (1) SG187457A1 (pt)
WO (1) WO2009087978A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094499A1 (en) * 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
EP2494361B2 (en) * 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP3305813B1 (en) * 2009-11-11 2020-01-15 Ganymed Pharmaceuticals GmbH Antibodies specific for claudin 6 (cldn6)
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
ES2682078T3 (es) * 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
CN114441757A (zh) 2011-04-01 2022-05-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
PT3026064T (pt) * 2011-05-13 2018-12-17 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Anticorpos para tratamento de cancro que expressa claudina 6
HUE028603T2 (en) 2011-05-13 2016-12-28 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
SG11201400916XA (en) 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
KR102084806B1 (ko) 2012-02-17 2020-03-04 시애틀 지네틱스, 인크. 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
JP2014193853A (ja) * 2013-03-01 2014-10-09 Japan Health Sciences Foundation 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN105814079B (zh) 2013-08-30 2021-02-09 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
PE20160870A1 (es) * 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
CN105940107B (zh) 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
PT3126381T (pt) * 2014-04-01 2019-04-18 Ganymed Pharmaceuticals Ag Imunorrecetores e epítopos de células t específicos da claudina-6
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
WO2018005697A1 (en) * 2016-06-29 2018-01-04 The Regents Of The University Of California Antibodies specific to sonic hedgehog and method of use thereof
CN110267984A (zh) * 2016-12-28 2019-09-20 国立大学法人大阪大学 抗紧密连接蛋白-2单克隆抗体
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
DK3826667T3 (da) * 2017-09-18 2024-07-22 Univ California Claudin6-antistoffer og fremgangsmåder til behandling af kræft
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
EP3735463A4 (en) * 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
TWI884192B (zh) 2019-12-05 2025-05-21 美商西健公司 抗αＶβ６抗體及抗體-藥物結合物
CR20220540A (es) 2020-03-31 2022-12-07 Chugai Pharmaceutical Co Ltd Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
AU2021374036A1 (en) * 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
EP4302777A4 (en) * 2021-03-05 2025-07-02 Shanghai Genbase Biotechnology Co Ltd ANTI-CLDN6 ANTIBODY AND ITS USE
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JPWO2023053282A1 (pt) 2021-09-29 2023-04-06
WO2024022512A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Claudin-6 binding moieties and uses thereof
AU2023324667A1 (en) * 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
AR130904A1 (es) 2022-10-31 2025-01-29 Astellas Pharma Inc Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
EP4707305A1 (en) * 2023-05-12 2026-03-11 Pediatric Immunity and Healthcare (Guangzhou) Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
AU2024274880A1 (en) 2023-05-25 2026-01-15 The Regents Of The University Of California Methods of treating cancer
TW202545994A (zh) * 2024-02-01 2025-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗cldn6抗體、其抗體-藥物偶聯物及其醫藥用途
CN118812714B (zh) * 2024-08-21 2025-05-27 广州百吉生物制药有限公司 一种紧密连接蛋白抗体b3及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6830894B1 (en) * 1998-11-03 2004-12-14 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
EP1572091A4 (en) * 2002-07-09 2008-03-05 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
JP2007020155A (ja) 2005-06-08 2007-01-25 Canon Inc 画像処理装置、画像処理方法、プログラム、及び記憶媒体
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
JP5060068B2 (ja) 2006-06-23 2012-10-31 一般財団法人ファインセラミックスセンター 固体酸化物形燃料電池及びその製造方法

Also Published As

Publication number Publication date
EP4282428A3 (en) 2024-03-20
EP3064512A3 (en) 2016-10-19
EP2241578A1 (en) 2010-10-20
RU2010133547A (ru) 2012-02-20
CN101918450A (zh) 2010-12-15
EP4282428A2 (en) 2023-11-29
EP3064512B1 (en) 2023-08-30
EP3064512C0 (en) 2023-08-30
MX2010007500A (es) 2010-10-20
US9274119B2 (en) 2016-03-01
EP3064512A2 (en) 2016-09-07
WO2009087978A1 (ja) 2009-07-16
US20110059469A1 (en) 2011-03-10
CA2711557A1 (en) 2009-07-16
EP2241578B1 (en) 2016-04-20
KR20100116179A (ko) 2010-10-29
EP2241578A4 (en) 2012-09-12
AU2009203464A1 (en) 2009-07-16
JPWO2009087978A1 (ja) 2011-05-26
JP5848863B2 (ja) 2016-01-27
SG187457A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
IL212175B (en) Muc1* antibodies
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
HUE056626T2 (hu) Antitestkészítmény
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
EP2358392A4 (en) ANTIBODY FORMULATION
PT2406284T (pt) Anticorpos anti-bcma
PT2813570T (pt) Resumo
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
PT3045471T (pt) Resumo
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
BRPI0909633A2 (pt) anticorpos anti-tyrp1
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
BRPI0817427A2 (pt) Anticorpo anti-bst2
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
BRPI0912769A2 (pt) anticorpos anti-pirb
DE112009001946A5 (de) Mobelauszugsführung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.